Antibe Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Antibe Therapeutics generated cash of -$16,305,000, which is less than the previous year. Cash used in financing activities reached the amount of $80,000 last year. Net change in cash is therefore -$28,052,000.
Cash Flow
| 2012 | -225.45K | 0 | 314.62K |
|---|---|---|---|
| 2016 | -2.76M | -688.95K | 3.44M |
| 2018 | -6.45M | -50.63K | 8.75K |
| 2020 | -11.93M | 98K | 12.00M |
| 2021 | -105K | -264K | 66.16M |
| 2023 | -16.30M | -11.82M | 80K |
ATE.TO Cash Flow Statement (2012 – 2022)
| 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 34.80M | 6.18M | 5.99M | 1.50M | 397.08K | 4.21K |
Operating activities | ||||||
Net income | -19.47M | -24.73M | -19.34M | -7.42M | -2.63M | -942.13K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 0 | 478K | 572K | 377.13K | 161.28K | 0 |
Stock-based compensation expense | 2.80M | 3.98M | 3.37M | 692.99K | 515.11K | 0 |
| Deferred income tax benefit | 2.80M | 3.98M | 3.37M | 692.99K | 515.11K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 443 | -1.35M | -39K | -61.98K | -152.91K | 0 |
Inventories | -239K | 530K | -621K | -353.32K | 466.69K | 0 |
Accounts payable | -217K | -4.74M | 2.54M | -99.91K | -531.97K | 0 |
Cash generated by operating activities | -16.30M | -105K | -11.93M | -6.45M | -2.76M | -225.45K |
Investing activities | ||||||
Purchases Of Investments | -48.43M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -9K | 0 | -2K | -50.63K | -288.95K | 0 |
Acquisitions Net | 319K | 0 | 0 | 0 | -400K | 0 |
Cash generated by investing activities | -11.82M | -264K | 98K | -50.63K | -688.95K | 0 |
Financing activities | ||||||
Common Stock Issued | 0 | 69.11M | 8.05M | 0 | 1.22M | 411.25K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -2.41M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 80K | 66.16M | 12.00M | 8.75K | 3.44M | 314.62K |
Net Change In Cash | -28.05M | 65.79M | 189K | 2.22M | -11.02K | 89.17K |
Cash at end of period | 6.75M | 71.97M | 6.18M | 3.72M | 386.06K | 93.38K |
| Data source | Data source | Data source | Data source | Data source | Data source |